Ambulatory Neuroproprioceptive Facilitation and Inhibition Physical Therapy Improves Clinical Outcomes in Multiple Sclerosis and Modulates Serum Level of Neuroactive Steroids: A Two-Arm Parallel-Group Exploratory Trial

Overview

Journal Life (Basel)

Specialty Biology

Date 2020 Nov 4

PMID 33142850

Citations 4

Authors

Gabriela Angelova

Tereza Skodova

Terezie Prokopiusova

Magdalena Markova

Natalia Hruskova

Marie Prochazkova

Marketa Pavlikova

Sarka Spanhelova

Ivana Stetkarova

Marie Bicikova

Lucie Kolatorova

Kamila rasova

Affiliations

Soon will be listed here.

Abstract

Methods: In total, 44 patients with multiple sclerosis were randomly divided into two groups. Each group underwent a different kind of two months ambulatory therapy (Motor program activating therapy and Vojta's reflex locomotion). During the following two months, participants were asked to continue the autotherapy. Primary (serum level of cortisol, cortisone, 7α-OH-DHEA, 7β-OH-DHEA, 7-oxo-DHEA, DHEA) and secondary (balance, cognition and patient-reported outcomes) outcomes were examined three times (pre, post, and washout assessments).

Results: In both groups, there is a decreasing trend of 7-oxo-DHEA concentration in post-assessment and 7β-OH-DHEA in washout versus pre-assessment. A higher impact on neuroactive steroids is visible after Vojta's reflex locomotion. As for clinical outcomes, the Paced Auditory Serial Addition Test and Multiple Sclerosis Impact Scale significantly improved between post-assessment and washout assessment. The improvement was similar for both treatments.

Conclusions: Neuroproprioceptive facilitation and inhibition improved the clinical outcomes and led to non-significant changes in neuroactive steroids. Trial registration (NCT04379193).

Citing Articles

Virtual reality-based neuroproprioceptive physiotherapy in multiple sclerosis: a protocol for a double-arm randomised assessor-blinded controlled trial on upper extremity function, postural function and quality of life, with molecular and functional....

Miznerova B, Reissigova J, Vasa L, Frank J, Hudec M, Rodina L BMJ Open. 2025; 15(1):e088046.

PMID: 39788766 PMC: 11752059. DOI: 10.1136/bmjopen-2024-088046.

Critical review of the evidence for Vojta Therapy: a systematic review and meta-analysis.

Sanchez-Gonzalez J, Sanz-Esteban I, Menendez-Pardinas M, Navarro-Lopez V, Sanz-Mengibar J Front Neurol. 2024; 15:1391448.

PMID: 38711552 PMC: 11070493. DOI: 10.3389/fneur.2024.1391448.

People with newly diagnosed multiple sclerosis benefit from a complex preventative intervention-a single group prospective study with follow up.

Hruskova N, Berchova Bimova K, Smith A, Skodova T, Bicikova M, Kolatorova L Front Neurol. 2024; 15:1373401.

PMID: 38660088 PMC: 11039797. DOI: 10.3389/fneur.2024.1373401.

Impact of reflex locomotion and the Bobath concept on clinical and biomolecular parameters in people with multiple sclerosis: study protocol for a randomized controlled trial.

Abreu-Corrales A, Velasco A, Cuesta-Gomez A, Sanchez-Gonzalez J Front Neurol. 2023; 14:1209477.

PMID: 37602251 PMC: 10438460. DOI: 10.3389/fneur.2023.1209477.

Lactate Threshold Training Program on Patients with Multiple Sclerosis: A Multidisciplinary Approach.

Amato A, Ragonese P, Ingoglia S, Schiera G, Schiro G, Di Liegro C Nutrients. 2021; 13(12).

PMID: 34959834 PMC: 8704660. DOI: 10.3390/nu13124284.

References

BAULIEU E, Schumacher M . Progesterone as a neuroactive neurosteroid, with special reference to the effect of progesterone on myelination. Steroids. 2000; 65(10-11):605-12. DOI: 10.1016/s0039-128x(00)00173-2. View

Michelson D, Stone L, Galliven E, Magiakou M, Chrousos G, Sternberg E . Multiple sclerosis is associated with alterations in hypothalamic-pituitary-adrenal axis function. J Clin Endocrinol Metab. 1994; 79(3):848-53. DOI: 10.1210/jcem.79.3.8077372. View

Akwa Y, Young J, Kabbadj K, Sancho M, Zucman D, Vourch C . Neurosteroids: biosynthesis, metabolism and function of pregnenolone and dehydroepiandrosterone in the brain. J Steroid Biochem Mol Biol. 1991; 40(1-3):71-81. DOI: 10.1016/0960-0760(91)90169-6. View

Allolio B, Arlt W . DHEA treatment: myth or reality?. Trends Endocrinol Metab. 2002; 13(7):288-94. DOI: 10.1016/s1043-2760(02)00617-3. View

rasova K, Prochazkova M, Tintera J, Ibrahim I, Zimova D, Stetkarova I . Motor programme activating therapy influences adaptive brain functions in multiple sclerosis: clinical and MRI study. Int J Rehabil Res. 2014; 38(1):49-54. DOI: 10.1097/MRR.0000000000000090. View

El Kihel L . Oxidative metabolism of dehydroepiandrosterone (DHEA) and biologically active oxygenated metabolites of DHEA and epiandrosterone (EpiA)--recent reports. Steroids. 2011; 77(1-2):10-26. DOI: 10.1016/j.steroids.2011.09.008. View

Morfin R, Lafaye P, Cotillon A, Nato F, Chmielewski V, Pompon D . 7 alpha-hydroxy-dehydroepiandrosterone and immune response. Ann N Y Acad Sci. 2001; 917:971-82. DOI: 10.1111/j.1749-6632.2000.tb05464.x. View

Hampl R, Hill M, Sterzl I, Starka L . Immunomodulatory 7-hydroxylated metabolites of dehydroepiandrosterone are present in human semen. J Steroid Biochem Mol Biol. 2001; 75(4-5):273-6. DOI: 10.1016/s0960-0760(00)00175-8. View

Chahal H, Drake W . The endocrine system and ageing. J Pathol. 2007; 211(2):173-80. DOI: 10.1002/path.2110. View

10.

Buford T, Willoughby D . Impact of DHEA(S) and cortisol on immune function in aging: a brief review. Appl Physiol Nutr Metab. 2008; 33(3):429-33. DOI: 10.1139/H08-013. View

11.

Friess E, Schiffelholz T, Steckler T, Steiger A . Dehydroepiandrosterone--a neurosteroid. Eur J Clin Invest. 2001; 30 Suppl 3:46-50. DOI: 10.1046/j.1365-2362.2000.0300s3046.x. View

12.

Hobart J, Riazi A, Lamping D, Fitzpatrick R, Thompson A . Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology. 2003; 60(1):31-6. DOI: 10.1212/wnl.60.1.31. View

13.

Pelissier M, Trap C, Malewiak M, Morfin R . Antioxidant effects of dehydroepiandrosterone and 7alpha-hydroxy-dehydroepiandrosterone in the rat colon, intestine and liver. Steroids. 2004; 69(2):137-44. DOI: 10.1016/j.steroids.2003.12.006. View

14.

Zhu J, Yung W, Kwok-Chong Chow B, Chan Y, Wang J . The cerebellar-hypothalamic circuits: potential pathways underlying cerebellar involvement in somatic-visceral integration. Brain Res Rev. 2006; 52(1):93-106. DOI: 10.1016/j.brainresrev.2006.01.003. View

15.

Morgan J, Corrigan F, Baune B . Effects of physical exercise on central nervous system functions: a review of brain region specific adaptations. J Mol Psychiatry. 2015; 3(1):3. PMC: 4461979. DOI: 10.1186/s40303-015-0010-8. View

16.

Feys P, Giovannoni G, Dijsselbloem N, Centonze D, Eelen P, Lykke Andersen S . The importance of a multi-disciplinary perspective and patient activation programmes in MS management. Mult Scler. 2016; 22(2 Suppl):34-46. DOI: 10.1177/1352458516650741. View

17.

rasova K, Dolezil D, Kalistova H, Kucera P, Juzova O, Zimova D . Physiotherapy as an immunoactive therapy? A pilot study. Neuro Endocrinol Lett. 2012; 33(1):67-75. View

18.

Doostzadeh J, Cotillon A, Benalycherif A, Morfin R . Inhibition studies of dehydroepiandrosterone 7 alpha- and 7 beta- hydroxylation in mouse liver microsomes. Steroids. 1998; 63(11):608-14. DOI: 10.1016/s0039-128x(98)00071-3. View

19.

Podsiadlo D, Richardson S . The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991; 39(2):142-8. DOI: 10.1111/j.1532-5415.1991.tb01616.x. View

20.

White L, Castellano V . Exercise and brain health--implications for multiple sclerosis: Part II--immune factors and stress hormones. Sports Med. 2008; 38(3):179-86. DOI: 10.2165/00007256-200838030-00001. View